Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 7,501-7,512 of 10,612

Behavioral study icon

CompletedNCT05101044

Open study to Improve Retention in Care for Persons With HIV Who Use Substances

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralOver 18 Years

Countries: United States
Sponsor: Brown University
Condition: Addiction

Drug study icon

TerminatedNCT02189915

Creatine Study for Female Meth Users

This study was terminated in the United States. It focuses on Addiction.

In United States

Addiction, DepressionDrugFrom 13 Years to 55 Years

Countries: United States
Sponsor: Perry Renshaw
Condition: Addiction, Depression

Drug study icon

WithdrawnNCT00204503

Depakote ER in people with Bipolar I or II Depression and Alcohol Abuse or Dependence

This study was withdrawn in the United States. It focuses on depression.

In United States

Bipolarity, DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: The University of Texas Medical Branch, Galveston
Condition: Bipolarity, Depression

Drug study icon

UnknownNCT05894902

Study of Oral SM-001 in Healthy Adults

This study has an unknown status in the United States. It is testing SM-001 for PTSD.

In United States

PTSD, DepressionDrugFrom 25 Years to 65 Years

Countries: United States
Sponsor: Advanced Integrative Medical Science Institute
Condition: PTSD, Depression

Drug study icon

UnknownNCT00583193

Duloxetine Monotherapy in the Treatment of PTSD

This study has an unknown status in the United States. It focuses on PTSD.

In United States

PTSDDrugOver 18 Years

Countries: United States
Sponsor: Canive, Jose M., M.D.
Condition: PTSD

Drug study icon

CompletedNCT01338818

Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

This study is completed in the United States, in Belgium, in Colombia, .... It focuses on ADHD.

In United States

ADHDDrugFrom 18 Years to 60 Years

Countries: United States, Belgium, Colombia, ...
Sponsor: Novartis Pharmaceuticals
Condition: ADHD

Drug study icon

CompletedNCT04143217

Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

This study is completed in the United States. It focuses on ADHD.

In United States

ADHDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Supernus Pharmaceuticals, Inc.
Condition: ADHD

Other study type icon

CompletedNCT02050854

Safety study of pharmacokinetics of Aripiprazole in schizophrenia

This study is completed in the United States. It is testing pharmacokinetics of Aripiprazole for schizophrenia.

In United States

Bipolarity, SchizophreniaObservationalFrom 18 Years to 55 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity, Schizophrenia

Drug study icon

CompletedNCT06235905

Of SPN-820 in Adults With Major Depressive Disorder

This study is completed in the United States. It focuses on depression.

In United States

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Navitor Pharmaceuticals, Inc.
Condition: Depression

Drug study icon

CompletedNCT00586573

Study of Namenda in Adult Subjects With ADHD and ADHD NOS

This study is completed in the United States. It is testing namenda for ADHD.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Massachusetts General Hospital
Condition: ADHD

Drug study icon

CompletedNCT06185985

Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

This study is completed in the United States. It focuses on ADHD.

In United States

ADHDDrugOver 18 Years

Countries: United States
Sponsor: Supernus Pharmaceuticals, Inc.
Condition: ADHD

Drug study icon

CompletedNCT02160262

Safety Study in Adults With ADHD

This study is completed in the United States. It focuses on ADHD.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Sumitomo Pharma America, Inc.
Condition: ADHD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.